Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: Focus on ibandronate 150 mg and risedronate 150 mg

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 2951-2960

  Epstein, Sol ^a,b   Jeglitsch, M ^c   McCloskey, E ^d  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Endocrine Associates Abington Hospital   (United States)

^c GLAXOSMITHKLINE   (Germany)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover markers; Ibandronate; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE; APATITE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; GERANYLTRANSFERASE; IBANDRONIC ACID; RISEDRONIC ACID;

ARTHRALGIA; BINDING AFFINITY; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE MARKER; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; FEMUR NECK; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; JAW OSTEONECROSIS; LUMBAR SPINE; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; RISK REDUCTION; UPPER ABDOMINAL PAIN; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72549117473     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903361307     Document Type: Review

References (62)

1. Kado D, Browner W, Palermo L. Vertebral fractures and mortality in older women. Arch Intern Med 1999;159:1215-1220
2. Empana JP, Dargent-Molina P, Bréart G, et al. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004;52:685-690 (Pubitemid 38596484)
3. Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733 (Pubitemid 44607392)
4. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIN consensus statement 2000;17:1-45
5. Cummings SR, Melton J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
6. International Osteroporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation 2003. Available at: http://www.osteofound.org/advocacy-policy/eu-policy-project/pdf/action-plan- 03-e.pdf [Last accessed 3 September 2009]
7. Melton J. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-1141 (Pubitemid 37294956)
8. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249 (Pubitemid 41094364)
9. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J Am Med Assoc 1999;282:1344-1352
10. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541 (Pubitemid 26411651)
11. Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822 (Pubitemid 46698462)
12. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-2082
13. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
14. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23:S81(Abstract 1288)
15. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42 (Pubitemid 350297180)
16. Greenspan S, Bone H, Ettinger M, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-339
17. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate of the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468 (Pubitemid 38133766)
18. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
19. Pasco JA, Kotowicz MA, Henry MJ, et al. Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study. Osteoporos Int 2004; 15:434-438 (Pubitemid 38843170)
20. Seeman E. Strontium ranelate: vertebral and non-vertebral fracture risk reduction. Curr Opin Rheumatol 2006;18(Suppl. 1):S17-20 (Pubitemid 44289185)
21. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934
22. Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-251 (Pubitemid 38781149)
23. Cramer J, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with post-menopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460 (Pubitemid 41368578)
24. Recker R, Gallagher R, MacCosbe P. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-861 (Pubitemid 40911458)
25. Reginster J-Y, Rebenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006;1:415-423
26. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. JCEM 2007;92:1296-1394 (Pubitemid 46556401)
27. Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims database. Mayo Clin Proc 2006;81:1013-1022 (Pubitemid 44175011)
28. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-1903 (Pubitemid 41803098)
29. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-310
30. Russell R, Watts N, Ebetino F, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical safety. Osteoporosis Int 2008;19:733-759
31. Russell R, Croucher P, Rogers M. Bisphosphonates: pharmacology, mechanisms of action in clinical uses. Osteoporos Int 1999;2:S66-S80 (Pubitemid 29231759)
32. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997;21:191-199
33. Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007;41(Suppl. 1):S3-8
34. Leu C, Luegmayr E, Freedman L, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006;38:628-636
35. Bauss F, Wagner M, Hothorn L. Total administered dose of ibandronate determines its effect on bone mass and architecture in overestomised aged rats. J Rheum 2002;29:990-998 (Pubitemid 34493506)
36. Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768-1778 (Pubitemid 29455826)
37. Müller R, Hannan M, Smith SY, et al. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 2004;19:1787-1796 (Pubitemid 41103429)
38. Smith SY, Recker RR, Hannan M, et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003;32:45-55 (Pubitemid 36173811)
39. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1 year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322 (Pubitemid 41033514)
40. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42 (Pubitemid 350297180)
41. Brody BA, Dickey N, Ellenberg SS, et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 2003;18:1105-1109
42. Temple RJ. Study designs in osteoporosis. J Bone Miner Res 2003;18:1129-1132
43. Hochberg M, Greenspan S, Wasnich R. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metabol 2002;87:1586-1592 (Pubitemid 34615244)
44. Wasnich R, Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metabol 2000;85:231-246 (Pubitemid 32268819)
45. European Medicines Agency 2005 Guideline on the Evaluation of New Medicinal Products in the Treatment of Osteoporosis. Available at: www. emea.eu.int/pdfs/human/ewp/ 055295en.pdf [last accessed 22 April 2009]
46. Silverman SL, Cummings SR, Watts N. Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 2008;23:159-165
47. US Dept of Health and Human Services. Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General. October 14, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth [Last accessed 3 September 2009]
48. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005;3:103-110
49. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340
50. Risedronate 1998 US prescribing information. Available at: http://www.actonel.com/prescribinginformation.jsp [Last accessed 3 September 2009]
51. Ste-Marie L, Brown J, Beary J, et al. Once-a-month risedronate is as effective as oral daily 5mg risedronate in postmenopausal osteoporosis: Phase II study results. Osteoporos Int 2006;17(Suppl. 2):S210-11 [abstract]
52. Bauss F, Schimmer R. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeut Clin Risk Manag 2006;2:3-18 (Pubitemid 43950061)
53. Gieschke R, Reginster J-Y. Successful prediction of biomarker response to oral monthly ibandronate. Osteoporosis Int 2004;15:S97(Abstract P359SU)
54. Reginster J-Y, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metabol 2005;90:5018-5024 (Pubitemid 41262248)
55. Barrett J, Worth E, Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-965 (Pubitemid 39096810)
56. Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of oncemonthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661
57. Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008;27:955-960
58. Miller PD, Cooper C, Neate C, et al. Long-term efficacy of monthly oral ibandronate: results from the MOBILE LTE study. Osteoporos Int 2008;19(Suppl. 2):299(Abstract P218TH)
59. Felsenberg D, Czerwinski E, Stakkestad J, et al. Efficacy of monthly oral ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporos Int 2009;20(Suppl. 1):S15(Abstract 0C32)
60. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-297
61. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of nonvertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of Phase III studies. Curr Med Res Opin 2008; 24:237-245
62. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-899 (Pubitemid 38581135)